07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peripheral benzodiazepine receptor (TSPO; PBR); Mdm2 p53 binding protein homolog (MDM2; HDM2)

Cancer INDICATION: Brain cancer In vitro studies identified an inhibitor of MDM2 /p53 binding and TSPO that could help treat glioblastoma. Chemical synthesis and in vitro testing of 2-phenylindolylglyoxylyl dipeptides identified a compound that bound...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Trophos, Roche deal

Roche will acquire Trophos for ÿ120 million ($142 million) up front and up to ÿ350 million ($414 million) in milestones. Roche gains olesoxime, a small molecule with cholesterol-like structure that interacts with the mitochondrial permeability...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

TRO40303: Phase II ongoing

Trophos completed treatment in a double-blind, placebo-controlled, European Phase II trial evaluating a single dose of 6 mg/kg IV TRO40303 in 165 patients undergoing percutaneous coronary intervention (PCI) to treat a first acute ST-segment elevation...
07:00 , Jun 6, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Peripheral benzodiazepine receptor (TSPO; PBR) Mouse studies suggest TSPO ligands could be used to treat AD. TSPO ligands have been shown to...
07:00 , Apr 29, 2013 |  BioCentury  |  Strategy

Zerhouni's progress report

When Elias Zerhouni joined Sanofi as the head of R&D in January 2011, the former NIH director decided the pharma's pipeline needed to be pruned and refocused around disease pathways. Two years into the job,...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

TRO40303: Phase II started

Trophos began a double-blind, placebo-controlled, European Phase II trial to evaluate a single dose of 6 mg/kg IV TRO40303 in 180 patients undergoing percutaneous transluminal coronary angioplasty. The trial is part of MitoCare, an EU-funded...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Clinical News

TRO40303: Phase I data

A placebo-controlled Phase I trial in 72 healthy volunteers showed that single escalating-doses of IV TRO40303 were safe. Trophos plans to start a Phase II trial of TRO40303 to treat acute myocardial infarction (AMI) in...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

TRO40303: Phase I started

Trophos began a placebo-controlled Phase I trial to evaluate single-escalating doses of IV TRO40303 in 64 healthy volunteers. Trophos S.A. , Marseille, France   Product: TRO40303   Business: Cardiovascular   Molecular target: Peripheral benzodiazepine receptor...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

TLN-4601: Phase II discontinued

Thallion discontinued an open-label Phase II trial after a planned interim analysis showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601 demonstrated stable disease after two 3-week cycles...